Doximity, Inc. (NASDAQ:DOCS - Get Free Report) Director Regina M. Benjamin sold 10,000 shares of the firm's stock in a transaction dated Wednesday, June 25th. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00. Following the completion of the sale, the director now owns 16,618 shares of the company's stock, valued at $997,080. This trade represents a 37.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Doximity Price Performance
DOCS traded up $0.78 during trading on Friday, reaching $61.19. 4,819,178 shares of the company's stock were exchanged, compared to its average volume of 2,167,619. The company's fifty day simple moving average is $56.04 and its 200-day simple moving average is $58.68. Doximity, Inc. has a 1 year low of $25.00 and a 1 year high of $85.21. The stock has a market capitalization of $11.49 billion, a P/E ratio of 61.19, a price-to-earnings-growth ratio of 4.10 and a beta of 1.33.
Doximity (NASDAQ:DOCS - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.11. Doximity had a return on equity of 21.75% and a net margin of 36.60%. During the same quarter in the previous year, the company earned $0.25 earnings per share. The business's revenue for the quarter was up 17.1% compared to the same quarter last year. Equities analysts forecast that Doximity, Inc. will post 0.99 EPS for the current year.
Institutional Investors Weigh In On Doximity
Several hedge funds have recently modified their holdings of DOCS. FMR LLC raised its stake in shares of Doximity by 37.6% during the 4th quarter. FMR LLC now owns 9,409,313 shares of the company's stock worth $502,363,000 after buying an additional 2,571,580 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in shares of Doximity by 708.7% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,510,416 shares of the company's stock valued at $80,641,000 after acquiring an additional 1,323,634 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Doximity in the first quarter worth approximately $65,702,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Doximity by 130.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,966,801 shares of the company's stock worth $114,133,000 after purchasing an additional 1,113,076 shares in the last quarter. Finally, Invesco Ltd. raised its stake in Doximity by 525.1% in the 4th quarter. Invesco Ltd. now owns 1,272,403 shares of the company's stock valued at $67,934,000 after purchasing an additional 1,068,849 shares during the last quarter. 87.19% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on DOCS shares. Morgan Stanley reduced their target price on shares of Doximity from $71.00 to $60.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 24th. KeyCorp lowered their target price on Doximity from $83.00 to $70.00 and set an "overweight" rating for the company in a report on Wednesday, April 16th. Needham & Company LLC dropped their price target on Doximity from $82.00 to $67.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Truist Financial decreased their price objective on Doximity from $58.00 to $52.00 and set a "hold" rating for the company in a report on Friday, May 16th. Finally, Raymond James Financial dropped their target price on shares of Doximity from $83.00 to $65.00 and set an "outperform" rating on the stock in a report on Friday, May 16th. Eleven research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $63.11.
Check Out Our Latest Stock Report on Doximity
About Doximity
(
Get Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
